Literature DB >> 17968177

Mechanism of salutary effects of finasteride on post-traumatic immune/inflammatory response: upregulation of estradiol synthesis.

Michael Frink1, Ya-Ching Hsieh, Shunhua Hu, Chi-Hsun Hsieh, Hans-Christoph Pape, Mashkoor A Choudhry, Martin G Schwacha, Kirby I Bland, Irshad H Chaudry.   

Abstract

OBJECTIVE: The aim of this study was to evaluate whether pretreatment with finasteride, a 5alpha-reductase inhibitor, improves immune functions after trauma-hemorrhage. SUMMARY BACKGROUND DATA: A number of studies have provided evidence for a gender dimorphism in host defense after trauma. Under stress conditions, such as trauma-hemorrhage, androgenic hormones have immunosuppressive effects, leading to increased susceptibility to sepsis, morbidity, and mortality. Testosterone is converted by 5alpha-reductase to 5alpha-dihydrotestosterone (DHT), a more potent androgen.
METHODS: Male C3H/HeN mice (8-10 weeks) were randomly assigned to receive finasteride or vehicle for 2 days and were then subjected to trauma-hemorrhage or sham operation. Trauma-hemorrhage was induced by a midline laparotomy and approximately 90 minutes of hemorrhagic shock (blood pressure, 35 mm Hg), followed by fluid resuscitation. Animals were killed 2 hours after resuscitation or sham procedure. Plasma levels and Kupffer cell production of cytokines (TNF-alpha, IL-6, IL-10, MCP-1, KC, and MIP-1alpha), lung neutrophil infiltration, and edema were evaluated.
RESULTS: Finasteride administration prevented the increase in cytokine plasma levels, decreased DHT, and increased 17beta-estradiol plasma concentrations. In addition, neutrophil infiltration and edema formation in the lung were reduced by finasteride. The salutary effects of finasteride were abrogated after coadministration with an estrogen receptor inhibitor (ICI 182,780). Increased Kupffer cell cytokine production normally observed after trauma-hemorrhage was prevented by treatment with finasteride.
CONCLUSION: These results suggest that inhibition of 5alpha-reductase leads to the conversion of testosterone to 17beta-estradiol, which produces salutary effects on the post-traumatic immune response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17968177     DOI: 10.1097/SLA.0b013e318158fca0

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  6 in total

1.  Mechanism of the salutary effects of estrogen on kupffer cell phagocytic capacity following trauma-hemorrhage: pivotal role of Akt activation.

Authors:  Chi-Hsun Hsieh; Eike A Nickel; Jianguo Chen; Martin G Schwacha; Mashkoor A Choudhry; Kirby I Bland; Irshad H Chaudry
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

2.  Does gender influence outcomes in critically ill patients?

Authors:  Martin K Angele; Sebastian Pratschke; Irshad H Chaudry
Journal:  Crit Care       Date:  2012-06-13       Impact factor: 9.097

Review 3.  Experimental trauma models: an update.

Authors:  Michael Frink; Hagen Andruszkow; Christian Zeckey; Christian Krettek; Frank Hildebrand
Journal:  J Biomed Biotechnol       Date:  2011-01-26

4.  Novel Biomarker Candidates for Febrile Neutropenia in Hematological Patients Using Nontargeted Metabolomics.

Authors:  Marika Lappalainen; Jenna Jokkala; Auni Juutilainen; Sari Hämäläinen; Irma Koivula; Esa Jantunen; Kati Hanhineva; Kari Pulkki
Journal:  Dis Markers       Date:  2018-04-12       Impact factor: 3.434

Review 5.  Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review.

Authors:  Abdolreza Haghpanah; Fatemeh Masjedi; Mehdi Salehipour; Alireza Hosseinpour; Jamshid Roozbeh; Anahita Dehghani
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-05-18       Impact factor: 5.455

Review 6.  Inflammatory mediators in intra-abdominal sepsis or injury - a scoping review.

Authors:  Zhengwen Xiao; Crystal Wilson; Helen Lee Robertson; Derek J Roberts; Chad G Ball; Craig N Jenne; Andrew W Kirkpatrick
Journal:  Crit Care       Date:  2015-10-27       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.